Can we achieve a greater reduction of cardiovascular mortality and morbidity in patients already treated with renin-angiotensin system blockers?;¿es posible conseguir una mayor reducción de la morbimortalidad cardiovascular en los pacientes ya tratados con bloqueadores del sistema renina-angiotensina?

Medicina Clinica

Volumn 135, Issue 5, 2010, Pages 212-214

  De La Sierra, Alejandro ^a   Ruilope, Luis Miguel ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; HEART DEATH; HUMAN; MORBIDITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION;

EID: 77953911782     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2009.09.012     Document Type: Article

References (15)

1. V. Dzau The cardiovascular continuum and renin-angiotensin-aldosterone system blockade J Hypertens 23 2005 S9 S17 (Pubitemid 43179845)
2. A. De la Sierra, L.M. Ruilope, A. Coca, and M. Luque-Otero Relación entre el perfil de riesgo cardiovascular y la selección y utilización de los fármacos antihipertensivos Med Clin (Barc) 115 2000 41 45 (Pubitemid 30497844)
3. E. Falaschetti, M. Chaudhury, J. Mindell, and N. Poulter Continued improvement in hypertension management in England: Results from the Health Survey for England 2006 Hypertension 53 2009 480 485 (Pubitemid 43772327)
4. F. Nicotra, B. Wettermark, M.C. Sturkenboom, A. Parodi, R. Bellocco, and A. Ekbom Management of antihypertensive drugs in three European countries J Hypertens 27 2009 1917 1922
5. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
6. N.K. Hollenberg, H.H. Parving, G. Viberti, G. Remuzzi, S. Ritter, and S. Zelenkofske Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus J Hypertens 25 2007 1921 1926 (Pubitemid 47356634)
7. K. Rossing, K.J. Schjoedt, B.R. Jensen, F. Boomsma, and H.H. Parving Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 68 2005 1190 1198 (Pubitemid 43246436)
8. E. Burgess, N. Muirhead, P. René de Cotret, A. Chiu, V. Pichette, and S. Tobe Supramaximal dose of candesartan in proteinuric renal disease J Am Soc Nephrol 20 2009 893 900
9. M.A. Pfeffer, J.J.V. McMurray, E.J. Velázquez, J.L. Rouleau, L. Køber, A.P. Maggioni for the Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906 (Pubitemid 37409706)
10. J. Cohn, G. Tognoni for the Val-HeFT Investigators A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure N Eng J Med 345 2001 1667 1675 (Pubitemid 33126822)
11. J.J. McMurray, J. Östergren, K. Swedberg, C.B. Granger, P. Held, and E.L. Michelson Effects of candesartan on in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting- enzyme inhibitors: The Charm-Added trial Lancet 362 2003 767 771 (Pubitemid 37093916)
12. R. Kunz, C. Friedrich, M. Wolbers, and J.F. Mann Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med 148 2008 30 48 (Pubitemid 351688350)
13. K.H. Gradman, and R. Kad Renin inhibition in hypertension J Am Coll Cardiol 51 2008 519 528
14. D.L. Feldman, L. Jin, H. Xuan, A. Contrepas, Y. Zhou, and R.L. Webb Effects of aliskiren on blood pressure, albuminuria, and (pro) renin receptor expression in diabetic TG(mRen-2)27 rats Hypertension 52 2008 130 136
15. H.H. Parving, F. Persson, J.B. Lewis, E.J. Lewis, N.K. Hollenberg for the AVOID Study Investigators Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 2008 2433 2446 (Pubitemid 351793017)